Philipps-Universitaet Marburg

The clinic focuses on eye diseases, investigating conditions such as macular edema due to central retinal vein occlusion and moderate-to-severe thyroid eye disease, with the goal of refining treatment protocols and reducing injection burden.

• Ranibizumab injection optimization
• Peripheral laser photocoagulation adjunct
• Satralizumab efficacy in thyroid eye disease

Collaboration with Philipps-Universitaet Marburg enables multidisciplinary expertise and patient‑centered outcomes.

Research in hematologic and lymphatic diseases targets acute myeloid leukemia, early‑stage unfavorable classical Hodgkin lymphoma, large B‑cell lymphoma, and MSI‑high colorectal cancer, aiming to improve survival through innovative cellular and immunotherapies.

• CAR T cell therapy evaluation
• Checkpoint inhibitor strategies
• Lymphodepletion regimen optimization

With 50 investigators, the site advances precision oncology across multiple cancer types.

The department studies immune system diseases such as thyroid eye disease, employing novel biologics like satralizumab to assess efficacy and safety while seeking to lessen disease‑related disability.

• Subcutaneous immunotherapy trials
• Proptosis response assessment
• Safety profiling of new biologics

As an educational institution, the site integrates clinical insight with academic research.

Investigations into prostate cancer focus on metastatic hormone‑sensitive disease, comparing docetaxel dosing schedules and combining chemotherapy with darolutamide plus androgen deprivation therapy to enhance progression‑free survival.

• Docetaxel dosing comparisons
• Combination with androgen deprivation therapy
• Adverse event monitoring strategies

Commercial partnerships support the development of optimized therapeutic regimens.

The site addresses neoplasms including metastatic colorectal cancer, advanced HER2‑negative breast cancer, and melanoma, evaluating checkpoint inhibitors and combination regimens to extend overall survival and understand resistance patterns.

• Subcutaneous nivolumab/relatlimab study
• Combination immunotherapy trials
• Molecular resistance analysis in breast cancer

A total of 11 clinical trials contribute to a comprehensive oncology portfolio.

Efforts in nervous system diseases concentrate on refractory status epilepticus, testing adjunctive IV ganaxolone added to standard antiepileptic drugs to improve seizure control and patient safety.

• Adjunctive ganaxolone efficacy study
• Safety assessment in acute seizures
• Integration with standard of care protocols

The program aims to deliver faster, more effective interventions for life‑threatening seizures.